ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TRML Tourmaline Bio Inc

16.96
0.36 (2.17%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tourmaline Bio Inc NASDAQ:TRML NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.36 2.17% 16.96 16.96 20.13 17.19 16.44 16.64 174,882 22:16:11

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

23/05/2024 12:10pm

GlobeNewswire Inc.


Tourmaline Bio (NASDAQ:TRML)
Historical Stock Chart


From Jun 2024 to Jun 2024

Click Here for more Tourmaline Bio Charts.

Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference:

Jefferies Global Healthcare Conference, New YorkCorporate PresentationThursday, June 6, 2024 at 2:30 pm ET

A live webcast and replay will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com.

About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is TOUR006.

About TOUR006TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in TED and ASCVD as its first two indications, with additional diseases under consideration.

Contact:

Meru AdvisorsLee M. Sternlstern@meruadvisors.com

1 Year Tourmaline Bio Chart

1 Year Tourmaline Bio Chart

1 Month Tourmaline Bio Chart

1 Month Tourmaline Bio Chart

Your Recent History

Delayed Upgrade Clock